Protagonist Therapeutics, Inc (PTGX): Operating Cash Flow
$57.67M
Year ended 2025-12-31
$131.20M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $57.67M | -68.7% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $184.15M | n/m | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | -$70.24M | n/m | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | -$108.14M | n/m | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | -$107.86M | n/m | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | -$72.48M | n/m | 2023-03-15, From 2020-01-01 |
| 2019-12-31 | -$41.53M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$49.95M | n/m | 2021-03-10, From 2018-01-01 |
| 2017-12-31 | $3.87M | n/m | 2020-03-10, From 2017-01-01 |
| 2016-12-31 | -$29.97M | n/m | 2019-03-12, From 2016-01-01 |
| 2015-12-31 | -$14.38M | n/m | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | -$7.74M | n/a | 2017-03-07, From 2014-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $57.67M | -68.7% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $110.19M | n/m |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$52.43M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $4.93M | n/m |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $1.24M | -39.9% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | -$4.99M | n/m |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$171.27M | n/m |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | -$187.49M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$67.85M | n/m |
Compare PTGX, SEPN, AQST, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗